CANTICANTI home
Back to diseases

Disease hub

Lung cancer

Open Targets catalogue label: lung cancer

Pulmonary malignancy bucket (including common trial abbreviations where mirrored text matches). Absence of rows reflects database coverage, not a clinical assertion.

Data: Live structured evidence (Supabase)

Source catalogue
16347
Imported rows
—
Explorer-eligible
—
Targets w/ drugs
—
Open guided lookup (general disease context)
Also indexed as

NSCLC · SCLC · pulmonary carcinoma · lung cancer · MONDO_0008903 · lung cancer, protection against, autosomal dominant, somatic mutation · malignant lung tumour · adenocarcinoma of lung, somatic · adenocarcinoma of lung, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation · malignant neoplasm of lung · malignant neoplasm of the lung · malignant tumor of lung · malignant tumour of the lung · nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation · nonsmall cell lung cancer, susceptibility to, autosomal dominant, somatic mutation · malignant tumour of lung · malignant lung neoplasm · malignant lung tumor · nonsmall cell lung cancer, somatic · malignant tumor of the lung · lung cancer, somatic · lung cancer, resistance to, autosomal dominant, somatic mutation · lung cancer, susceptibility to, autosomal dominant, somatic mutation · cancer of lung · alveolar cell carcinoma · lung neoplasm · lung cancer, protection against · Nonsmall cell lung cancer · ICD9:162.4 · DOID:1324 · OMIM:211980 · NCIT:C7377 · ICD9:162.8 · MEDGEN:66885 · UMLS:C0242379 · ICD9:162.3 · SCTID:363358000 · ICD9:162.9 · ICD9:162.5

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible

Important limitations

  • Shared-target cross-indication paths show mechanistic adjacency only — they do not establish clinical benefit or recommend treatment.
  • Disease→target associations are scoped to this hub’s Open Targets umbrella concept; subtype evidence may be represented on separate catalogue pages.
  • Lung cancer here uses the umbrella MONDO lung-cancer concept. NSCLC/SCLC subtype evidence is not collapsed into this hub and may appear separately.
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations
16,347

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Measured from Open Targets on 2026-05-15

Imported evidence rows
—

Source evidence rows, not unique targets.

Explorer-eligible targets
—

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships
—

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs
—

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges
—

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.

Disease-aware regulatory approval

Regulator-backed indication status for Lung cancer. Trial phase is not approval.

No regulator-backed approval indication was resolved in Canti for the sampled drugs.

Currently indexed off-label and cross-indication drug evidence

Complete paths only — grouped by drug.

Showing 95 of 154 complete cross-indication paths · 10 of 43 drugs shown

10 of 43 drugs

10 of 43 drugs

Approval in another disease and a shared target or biomarker do not establish safety or clinical benefit in Lung cancer.